Small Company Offering and Sale of Securities Without Registration (d)
September 14 2020 - 4:03PM
Edgar (US Regulatory)
o
NoneEntity Type | 0001017491 | APRICUS BIOSCIENCES, INC. NEXMED INC |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
Name of Issuer |
SEELOS THERAPEUTICS, INC. |
Jurisdiction of Incorporation/Organization |
NEVADA |
|
Year of Incorporation/Organization |
|
x
| Over Five Years Ago |
|
o
| Within Last Five Years (Specify Year) | |
|
o
| Yet to Be Formed | |
2. Principal Place of Business and Contact Information |
Name of Issuer | |
SEELOS THERAPEUTICS, INC. | |
Street Address 1 | Street Address 2 |
300 PARK AVENUE | 12TH FLOOR |
City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
NEW YORK | NEW YORK | 10017 | (646) 998-6475 |
Last Name | First Name | Middle Name |
Mehra | Raj | |
Street Address 1 | Street Address 2 |
c/o Seelos Therapeutics, Inc. | 300 Park Avenue, 12th Floor |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Lian | Brian | |
Street Address 1 | Street Address 2 |
c/o Seelos Therapeutics, Inc. | 300 Park Avenue, 12th Floor |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Pascoe | Richard | W. |
Street Address 1 | Street Address 2 |
c/o Seelos Therapeutics, Inc. | 300 Park Avenue, 12th Floor |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
Dunn | Judith | |
Street Address 1 | Street Address 2 |
c/o Seelos Therapeutics, Inc. | 300 Park Avenue, 12th Floor |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
Last Name | First Name | Middle Name |
O'Connor | Daniel | J. |
Street Address 1 | Street Address 2 |
c/o Seelos Therapeutics, Inc. | 300 Park Avenue, 12th Floor |
City | State/Province/Country | ZIP/Postal Code |
New York | NEW YORK | 10022 |
Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
Clarification of Response (if Necessary) |
| |
o
| Agriculture | | Health Care |
o
| Retailing |
| Banking & Financial Services | |
x
| Biotechnology |
o
| Restaurants |
|
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
|
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
|
o
| Investing | |
o
| Pharmaceuticals | |
o
| Telecommunications |
|
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
|
o
| Pooled Investment Fund
| | | | | Travel |
|
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| Real Estate | |
o
| Lodging & Conventions |
|
o
| Commercial | |
o
| Tourism & Travel Services |
|
o
| Construction | |
o
| Other Travel |
|
o
| REITS & Finance |
o
| Other |
|
o
| Residential | |
|
o
| Other Real Estate | |
o
| Business Services | |
| Energy | |
|
o
| Coal Mining | |
|
o
| Electric Utilities | |
|
o
| Energy Conservation | |
|
o
| Environmental Services | |
|
o
| Oil & Gas | |
|
o
| Other Energy | |
Revenue Range | Aggregate Net Asset Value Range |
x
| No Revenues |
o
| No Aggregate Net Asset Value |
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
o
| Over $100,000,000 |
o
| Over $100,000,000 |
o
| Decline to Disclose |
o
| Decline to Disclose |
o
| Not Applicable |
o
| Not Applicable |
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
|
o
| Investment Company Act Section 3(c) |
x
| New Notice | Date of First Sale | 2020-09-09 |
o
| First Sale Yet to Occur |
Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
9. Type(s) of Securities Offered (select all that apply) |
o
| Pooled Investment Fund Interests |
o
| Equity |
o
| Tenant-in-Common Securities |
o
| Debt |
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| |
10. Business Combination Transaction |
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
|
Clarification of Response (if Necessary) | |
|
Minimum investment accepted from any outside investor | $ 0 USD |
Recipient | Recipient CRD Number |
o
| None |
Roth Capital Partners, LLC | 15407 |
(Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| |
Street Address 1 | Street Address 2 |
888 San Clemente Drive | Suite 400 |
City | State/Province/Country | ZIP/Postal Code |
Newport Beach | CALIFORNIA | 92660 |
State(s) of Solicitation |
o
| All States |
o
| Foreign/Non-US |
ILLINOIS FLORIDA NEW YORK |
13. Offering and Sales Amounts |
Total Offering Amount | $ 5584950 USD |
o
Indefinite |
Total Amount Sold | $ 0 USD | |
Total Remaining to be Sold | $ 5584950 USD |
o
Indefinite |
|
Clarification of Response (if Necessary) |
Represents aggregate exercise price of warrants to purchase 6,648,750 shares of the Company's common stock, which were issued in connection with an offering of 8,865,000 shares of the Company's common stock issued in a registered direct offering. |
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering
| |
| Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 13 |
15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
Sales Commissions | $ 490235 USD |
o
| Estimate |
Finders' Fees | $ 80000 USD |
o
| Estimate |
|
Clarification of Response (if Necessary) |
$490,234.50 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $80,000 is for the reimbursement of expenses incurred by the placement agent. |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| $ 0 USD |
o
Seelos Therapeutics (NASDAQ:SEEL) Historical Stock Chart From Mar 2024 to Apr 2024
Seelos Therapeutics (NASDAQ:SEEL) Historical Stock Chart From Apr 2023 to Apr 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|